Provided by Tiger Trade Technology Pte. Ltd.

Charles River Laboratories

273.00
-5.3500-1.92%
Post-market: 277.694.69+1.72%18:54 EDT
Volume:764.67K
Turnover:208.79M
Market Cap:13.03B
PE:-55.93
High:275.88
Open:275.38
Low:272.06
Close:278.35
52wk High:303.31
52wk Low:144.26
Shares:47.74M
Float Shares:47.20M
Volume Ratio:1.09
T/O Rate:1.62%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.8814
EPS(LYR):-2.9122
ROE:-7.52%
ROA:4.11%
PB:4.59
PE(LYR):-93.75

Loading ...

Charles River price target raised to $220 from $210 at Barclays

TIPRANKS
·
May 08

Barclays Reaffirms Their Buy Rating on Charles River Labs (CRL)

TIPRANKS
·
May 08

U.S. RESEARCH ROUNDUP-Applied Materials, McDonald's, McKesson

Reuters
·
May 08

Charles River Laboratories International Inc : Baird Raises Target Price to $213 From $200

THOMSON REUTERS
·
May 08

Charles River Laboratories International Inc : JP Morgan Raises Target Price to $180 From $160

THOMSON REUTERS
·
May 08

Charles River Laboratories International Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 08

Charles River Exec Says Any Decision to Expand China Structure Will Be Based on Cost, Demand, Growth Rates and Geopolitical Considerations

THOMSON REUTERS
·
May 07

Charles River Exec Says Recent Increase in Biopharma M&a Activity Has Provided Additional Source of Capital Infusion and Exit Strategy for Biotechs

THOMSON REUTERS
·
May 07

Charles River Exec Says Demand From Start-up Biotechs Remains Tepid as Earlier Stage and Seed Funding Environment Remains Constrained

THOMSON REUTERS
·
May 07

Charles River Exec Says Improved Demand in China Seen as Indication That Chinese Market Is Rebounding and Accelerating

THOMSON REUTERS
·
May 07

Charles River Exec Says Co Closely Monitoring China Market Given Accelerated Drug Innovation and in-Licensing Activity but Also Looking at Geopolitical Risks

THOMSON REUTERS
·
May 07

Charles River Exec Says Government Funding Pressures at Nih Have Modestly Impacted Client Spending

THOMSON REUTERS
·
May 07

Charles River Exec Says Revenue From Global Biopharmaceutical Client Segment Increased in the First Quarter - Conf Call

THOMSON REUTERS
·
May 07

Charles River beats quarterly estimates on steady demand for drug development services

Reuters
·
May 07

GUIDANCE: (CRL) Charles River Laboratories International Expects 2026 Non-GAAP EPS Range $10.80 - $11.30, vs. FactSet Est of $11.08

MT Newswires Live
·
May 07

Charles River Q1 Adjusted EPS USD 2.06 Vs. IBES Estimate USD 1.94

Reuters
·
May 07

Charles River Q1 revenue and adjusted EPS beat estimates

Reuters
·
May 07

Charles River Q1 FY26 turns to net loss of $14.8 million; revenue rises 1.2% to $995.8 million

Reuters
·
May 07

Charles River Q1 Adj. EPS $2.06 Beats $1.94 Estimate, Sales $995.830M Beat $977.486M Estimate

Benzinga Earnings
·
May 07

Charles River Laboratories International Inc - Reaffirms 2026 Guidance for Organic Revenue and Non-Gaap Earnings per Share

THOMSON REUTERS
·
May 07